Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Incidence and Risk Factors of Platinum-Based Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-Analysis.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE
    • Publication Information:
      Publication: 2021- : Basel, Switzerland : MDPI
      Original Publication: Toronto : Multimed, c1994-
    • Subject Terms:
      Vomiting*/chemically induced ; Vomiting*/epidemiology ; Nausea*/chemically induced ; Nausea*/epidemiology ; Antineoplastic Agents*/adverse effects ; Neoplasms*/drug therapy ; Platinum*/adverse effects; Humans ; Risk Factors ; Incidence ; Female
    • Abstract:
      Background: Platinum-based chemotherapy significantly increases the risk of nausea and vomiting, which can impair the treatment's efficacy and the patient's quality of life. This meta-analysis examines the incidence and risk factors of platinum-based chemotherapy-induced nausea and vomiting (PINV) in patients treated with this chemotherapy.
      Methods: This systematic review and meta-analysis were conducted in accordance with the PRISMA 2020 guidelines. We conducted a literature search in the databases PubMed, Embase, Web of Science, WanFang, China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure (CNKI), and Chinese Medical Association Journal Database (CMAJD) through to 20 January 2025. Studies that reported the incidence and identified risk factors of nausea and vomiting specifically in patients receiving platinum-based chemotherapy were included in the review. The data were extracted independently by two reviewers. The odds ratios (ORs) for each risk factor were calculated from the included studies. Sensitivity analyses and additional subgroup analyses were performed to ensure the robustness of our findings.
      Results: This meta-analysis included 32 studies involving 14,207 participants. Female sex (OR = 2.363, 95% CI = 1.363-4.096, p = 0.002), anxiety (OR = 1.689, 95% CI = 1.057-2.700, p = 0.028), fatigue (OR = 1.413, 95% CI = 1.145-1.744, p = 0.001), motion sickness (OR = 1.816, 95% CI = 1.266-2.605, p = 0.001), and a history of vomiting during chemotherapy (OR = 2.728, 95% CI = 1.468-5.069, p = 0.002) were significantly associated with an increased risk of PINV.
      Conclusion: Female sex, anxiety, fatigue, motion sickness, and a history of vomiting during chemotherapy increase the risk of PINV during platinum-based treatments.
    • References:
      Ann Oncol. 2016 Sep;27(suppl 5):v119-v133. (PMID: 27664248)
      J Oncol Pract. 2012 May;8(3):136-40. (PMID: 22942805)
      Dalton Trans. 2018 May 15;47(19):6645-6653. (PMID: 29632935)
      Support Care Cancer. 2012 Jan;20(1):107-17. (PMID: 21258948)
      Neurogastroenterol Motil. 2019 Jun;31 Suppl 2:e13604. (PMID: 31241819)
      Pharmacogenomics. 2010 Jul;11(7):943-50. (PMID: 20602613)
      Support Care Cancer. 2019 Mar;27(3):1139-1147. (PMID: 30094732)
      Cancer Commun (Lond). 2023 Feb;43(2):246-256. (PMID: 36545810)
      BMC Pharmacol Toxicol. 2019 Jan 14;20(1):6. (PMID: 30642399)
      Gastroenterol Nurs. 2005 Nov-Dec;28(6):469-80. (PMID: 16418583)
      Support Care Cancer. 2018 May;26(5):1505-1513. (PMID: 29177570)
      J Clin Oncol. 2025 Mar 20;43(9):1123-1136. (PMID: 39621965)
      Support Care Cancer. 2005 Feb;13(2):117-21. (PMID: 15599779)
      Drug Saf. 1995 Oct;13(4):228-44. (PMID: 8573296)
      Support Care Cancer. 2002 Mar;10(2):88-95. (PMID: 11862498)
      Eur J Epidemiol. 2010 Sep;25(9):603-5. (PMID: 20652370)
      Zhonghua Zhong Liu Za Zhi. 2024 Apr 23;46(4):304-318. (PMID: 38644266)
      Ther Clin Risk Manag. 2015 May 05;11:713-29. (PMID: 25999723)
      Indian J Physiol Pharmacol. 2004 Jul;48(3):256-68. (PMID: 15648398)
      Pharmacoepidemiol Drug Saf. 2013 Dec;22(12):1345-51. (PMID: 24023040)
      Medicine (Baltimore). 2016 Jan;95(2):e2476. (PMID: 26765450)
      Support Care Cancer. 2006 Apr;14(4):354-60. (PMID: 16450086)
      Support Care Cancer. 2020 Jan;28(1):13-21. (PMID: 31388745)
      Front Pharmacol. 2024 Sep 13;15:1369442. (PMID: 39346558)
      Nutr Rev. 2013 Apr;71(4):245-54. (PMID: 23550785)
      N Engl J Med. 2008 Jun 5;358(23):2482-94. (PMID: 18525044)
      Endocr Relat Cancer. 2015 Aug;22(4):R219-33. (PMID: 26113607)
      Int J Colorectal Dis. 2020 Dec;35(12):2323-2329. (PMID: 32860080)
      EBioMedicine. 2021 Jul;69:103451. (PMID: 34161883)
      Cancer Res Treat. 2015 Oct;47(4):670-5. (PMID: 25672586)
      Asia Pac J Oncol Nurs. 2021 May 31;8(4):433-437. (PMID: 34159237)
      N Engl J Stat Data Sci. 2024 Oct;2(3):380-392. (PMID: 39991459)
      Am J Clin Nutr. 1988 Sep;48(3 Suppl):888-95. (PMID: 3046317)
      ESMO Open. 2024 Feb;9(2):102195. (PMID: 38458657)
      Clin Ther. 2020 Oct;42(10):1975-1982. (PMID: 32868036)
      Support Care Cancer. 2020 Nov;28(11):5343-5351. (PMID: 32130508)
      Nurs Res. 2012 Nov-Dec;61(6):405-12. (PMID: 22960588)
      J Pain Symptom Manage. 2014 Mar;47(3):542-50. (PMID: 23856100)
      Complement Ther Clin Pract. 2020 Aug;40:101213. (PMID: 32891289)
      Intern Med J. 2017 Jul;47(7):792-797. (PMID: 28321977)
      Cell Metab. 2020 Dec 1;32(6):938-950.e6. (PMID: 33207247)
      J Clin Oncol. 2020 Aug 20;38(24):2782-2797. (PMID: 32658626)
      PLoS One. 2017 Oct 10;12(10):e0184360. (PMID: 29016607)
      Int J Mol Sci. 2021 May 28;22(11):. (PMID: 34071460)
      JAMA Netw Open. 2024 Aug 1;7(8):e2426076. (PMID: 39106066)
      Am J Manag Care. 2017 Sep;23(14 Suppl):S259-S265. (PMID: 28978206)
      Palliat Med. 2012 Apr;26(3):275-82. (PMID: 21807751)
      Ann Behav Med. 2007 Feb;33(1):69-79. (PMID: 17291172)
      J Med Invest. 2020;67(3.4):338-342. (PMID: 33148912)
      BMC Cancer. 2021 Oct 16;21(1):1111. (PMID: 34656107)
      Support Care Cancer. 2002 Apr;10(3):237-46. (PMID: 11904789)
      Cell Host Microbe. 2022 Jun 8;30(6):809-823.e6. (PMID: 35439436)
      J Pain Symptom Manage. 2014 May;47(5):839-848.e4. (PMID: 24075401)
      JAMA Netw Open. 2020 Oct 1;3(10):e2021692. (PMID: 33112397)
      Biol Pharm Bull. 2016;39(11):1852-1858. (PMID: 27803457)
      J Acad Nutr Diet. 2016 May;116(5):819-27. (PMID: 26686816)
      Rev Saude Publica. 2020 Nov 09;54:106. (PMID: 33175025)
      Pain. 1992 Feb;48(2):137-146. (PMID: 1350338)
      Cureus. 2023 Aug 31;15(8):e44438. (PMID: 37664299)
      Biomed Res Int. 2015;2015:328636. (PMID: 26167483)
      Iran J Med Sci. 2022 Mar;47(2):95-106. (PMID: 35291438)
      Dis Esophagus. 2017 Feb 1;30(2):1-7. (PMID: 27001532)
      Zhonghua Zhong Liu Za Zhi. 2024 Jun 23;46(6):481-501. (PMID: 38679793)
      BMC Pediatr. 2005 Mar 24;5(1):3. (PMID: 15790392)
      Front Psychol. 2025 Jan 10;15:1435110. (PMID: 39868024)
      Adv Ther. 2023 Jul;40(7):3217-3226. (PMID: 37245189)
      Front Pharmacol. 2019 Apr 25;10:410. (PMID: 31133847)
      Support Care Cancer. 1998 May;6(3):221-7. (PMID: 9629873)
    • Grant Information:
      2023R41045 Zhejiang Provincial Xinmiao Talents Program; 82204979 National Natural Science Foundation of China; 2023ZR085 Zhejiang Province Traditional Chinese Medicine Science and Technology Plan Project
    • Contributed Indexing:
      Keywords: chemotherapy-induced nausea and vomiting; meta-analysis; platinum-based chemotherapy; risk factors; systematic review
    • Accession Number:
      0 (Antineoplastic Agents)
      49DFR088MY (Platinum)
    • Publication Date:
      Date Created: 20250625 Date Completed: 20250625 Latest Revision: 20251210
    • Publication Date:
      20260130
    • Accession Number:
      PMC12191659
    • Accession Number:
      10.3390/curroncol32060325
    • Accession Number:
      40558268